The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

This article is part of a special series investigating the GLP-1 agonist boom. Read more here. A growing number of studies show that semaglutide seems to have many beneficial effects in addition ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Right now, about 12% of American aged 18 or older (or 1 in 8 adults) are taking GLP-1 — glucagon-like peptide-1 — receptor agonists ... Mounjaro, Trulicity and other similar drugs work ...

“Conversely, inhibition of VTA dopamine neurons reduced consumption.” GLP-1 agonists, including semaglutide, mimic satiety signals in the brain, leading to reduced appetite. These drugs are ...

My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is 5 feet, 7 inches tall, and weighs 270 pounds. He is treating his fluid retention with 100 ...